Payment overview · 2025
General Payments
$1,483.56
69 reported records · 19 companies
Healthcare provider profile · identity verified
Than T Aung, MD
Allopathic & Osteopathic Physicians|Internal Medicine · REDDING, CA · NPI 1578504841
Verified facts
What the public records show
CMS Open Payments records show Than T Aung, MD received $1,483.56 in general payments during 2025 across 69 reported records.
Novo Nordisk Inc accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Mounjaro, Nexletol, Ozempic, Paxlovid, Rexulti, Shingrix, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Farxiga by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 405 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $203.63 | 13.7% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $203.35 | 13.7% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $183.14 | 12.3% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.37 | 9.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $114.12 | 7.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.10 | 5.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.42 | 5.5% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.49 | 4.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.25 | 4.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.64 | 4.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.00 | 3.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.54 | 3.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.62 | 2.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.22 | 2.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.27 | 1.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.49 | 1.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.37 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.50 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.04 | 1.2% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,463.58 | 68 |
| Long term medical supply or device loan | $19.98 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $180.49 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $180.49 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $119.53 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $119.14 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $119.14 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $114.12 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $114.12 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.55 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $83.82 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.10 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $70.00 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.67 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $68.49 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $60.25 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.64 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.94 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.94 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $49.00 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.54 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.18 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $43.62 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.93 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.27 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.49 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.46 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.46 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.04 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 204 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 160 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 75 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 144 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 79 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 164 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
132 | 36 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
204 | 33 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
164 | 125 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 27 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
405 | 86 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
79 | 75 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1280 | 333 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1177 | 296 |
| Amlodipine Besylate | Amlodipine Besylate | 994 | 266 |
| Losartan Potassium | Losartan Potassium | 753 | 208 |
| Gabapentin | Gabapentin | 695 | 172 |
| Lisinopril | Lisinopril | 618 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 607 | 168 |
| Pantoprazole Sodium | Pantoprazole Sodium | 499 | 133 |
| Furosemide | Furosemide | 471 | 151 |
| Omeprazole | Omeprazole | 443 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 418 | 114 |
| Carvedilol | Carvedilol | 413 | 96 |
| Eliquis | Apixaban | 405 | 86 |
| Montelukast Sodium | Montelukast Sodium | 378 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 38 |
| Baclofen | Baclofen | 361 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 98 |
| Simvastatin | Simvastatin | 344 | 94 |
| Metformin Hcl | Metformin Hcl | 316 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 282 | 54 |
| Meloxicam | Meloxicam | 278 | 80 |
| Trazodone Hcl | Trazodone Hcl | 277 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 273 | 70 |
| Potassium Chloride | Potassium Chloride | 262 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 69 |
| Doxycycline Hyclate | Doxycycline Hyclate | 234 | 128 |
| Prednisone | Prednisone | 218 | 119 |
| Azithromycin | Azithromycin | 211 | 146 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 58 |
| Farxiga | Dapagliflozin Propanediol | 204 | 33 |
| Tramadol Hcl | Tramadol Hcl | 203 | 54 |
| Glimepiride | Glimepiride | 192 | 57 |
| Pioglitazone Hcl | Pioglitazone Hcl | 185 | 50 |
| Alendronate Sodium | Alendronate Sodium | 179 | 49 |
| Ibandronate Sodium | Ibandronate Sodium | 179 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 39 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 164 | 125 |
| Bupropion Xl | Bupropion Hcl | 163 | 47 |
| Jardiance | Empagliflozin | 160 | 29 |
| Ezetimibe | Ezetimibe | 157 | 44 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 153 | 85 |
| Oxybutynin Chloride | Oxybutynin Chloride | 149 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 58 |
| Celecoxib | Celecoxib | 148 | 35 |
| Ozempic | Semaglutide | 144 | 27 |
| Sertraline Hcl | Sertraline Hcl | 136 | 30 |
| Donepezil Hcl | Donepezil Hcl | 135 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 134 | 40 |
| Memantine Hcl | Memantine Hcl | 133 | 27 |
| Synthroid | Levothyroxine Sodium | 132 | 36 |
| Finasteride | Finasteride | 130 | 35 |
| Levetiracetam | Levetiracetam | 126 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 26 |
| Famotidine | Famotidine | 118 | 30 |
| Cefdinir | Cefdinir | 114 | 82 |
| Sucralfate | Sucralfate | 114 | 34 |
| Estradiol | Estradiol | 113 | 39 |
| Doxepin Hcl | Doxepin Hcl | 111 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 22 |
| Enulose | Lactulose | 107 | 28 |
| Allopurinol | Allopurinol | 104 | 30 |
| Xarelto | Rivaroxaban | 104 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 39 |
| Acarbose | Acarbose | 101 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 100 | 73 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 43 |
| Cephalexin | Cephalexin | 98 | 75 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 98 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 96 | 39 |
| Pregabalin | Pregabalin | 96 | 23 |
| Januvia | Sitagliptin Phosphate | 95 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 21 |
| Meclizine Hcl | Meclizine Hcl | 93 | 33 |
| Mirtazapine | Mirtazapine | 91 | 18 |
| Atenolol | Atenolol | 90 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 57 |
| Mounjaro | Tirzepatide | 88 | 18 |
| Buspirone Hcl | Buspirone Hcl | 87 | 21 |
| Lovastatin | Lovastatin | 87 | 25 |
| Lorazepam | Lorazepam | 86 | 29 |
| Spironolactone | Spironolactone | 86 | 25 |
| Colestipol Hcl | Colestipol Hcl | 85 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 18 |
| Metformin Hcl Er | Metformin Hcl | 85 | 30 |
| Benazepril Hcl | Benazepril Hcl | 83 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 46 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 21 |
| Propranolol Hcl | Propranolol Hcl | 80 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 79 | 75 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 15 |
| Clonazepam | Clonazepam | 76 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 75 | 33 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 75 | 25 |
| Linzess | Linaclotide | 75 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 74 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 72 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 21 |
| Solifenacin Succinate | Solifenacin Succinate | 71 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 15 |
| Latanoprost | Latanoprost | 70 | 11 |
| Irbesartan | Irbesartan | 69 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 49 |
| Valacyclovir | Valacyclovir Hcl | 69 | 35 |
| Clonidine Hcl | Clonidine Hcl | 68 | 20 |
| Alprazolam | Alprazolam | 67 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 13 |
| Topiramate | Topiramate | 66 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 15 |
| Metolazone | Metolazone | 56 | 19 |
| Rexulti | Brexpiprazole | 54 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 17 |
| Lactulose | Lactulose | 51 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 13 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 16 |
| Warfarin Sodium | Warfarin Sodium | 49 | 13 |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 12 |
| Ibuprofen | Ibuprofen | 47 | 14 |
| Valsartan | Valsartan | 47 | suppressed |
| Amoxicillin | Amoxicillin | 45 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 15 |
| Terazosin Hcl | Terazosin Hcl | 43 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 11 |
| Budesonide | Budesonide | 38 | suppressed |
| Felodipine Er | Felodipine | 38 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 22 |
| Trimethoprim | Trimethoprim | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Modafinil | Modafinil | 34 | suppressed |
| Nystatin | Nystatin | 34 | 28 |
| Amantadine | Amantadine Hcl | 33 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 16 |
| Lidocaine | Lidocaine | 31 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 30 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 28 | 20 |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Phenytoin | Phenytoin | 28 | suppressed |
| Clotrimazole | Clotrimazole | 27 | 17 |
| Enoxaparin Sodium | Enoxaparin Sodium | 27 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 27 | 14 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 25 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 25 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | 13 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Roflumilast | Roflumilast | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 17 |
| Temazepam | Temazepam | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Ciclopirox | Ciclopirox | 21 | 12 |
| Risperidone | Risperidone | 21 | suppressed |
| Verapamil Sr | Verapamil Hcl | 21 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Levoxyl | Levothyroxine Sodium | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Nexletol | Bempedoic Acid | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,483.56 · 69 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE INSULINX, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, Rybelsus, SHINGRIX, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error